| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 4379 | 2018 |
| An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018 | 2560 | 2018 |
| Comprehensive molecular characterization of muscle-invasive bladder cancer AG Robertson, J Kim, H Al-Ahmadie, J Bellmunt, G Guo, AD Cherniack, ... Cell 171 (3), 540-556. e25, 2017 | 2213 | 2017 |
| Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy W Choi, S Porten, S Kim, D Willis, ER Plimack, J Hoffman-Censits, B Roth, ... Cancer cell 25 (2), 152-165, 2014 | 1643 | 2014 |
| The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma CJ Ricketts, AA De Cubas, H Fan, CC Smith, M Lang, E Reznik, R Bowlby, ... Cell reports 23 (1), 313-326. e5, 2018 | 817 | 2018 |
| Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer DY Oh, SS Kwek, SS Raju, T Li, E McCarthy, E Chow, D Aran, A Ilano, ... Cell 181 (7), 1612-1625. e13, 2020 | 490 | 2020 |
| Outcomes of active surveillance for men with intermediate-risk prostate cancer MR Cooperberg, JE Cowan, JF Hilton, AC Reese, HB Zaid, SP Porten, ... Journal of Clinical Oncology 29 (2), 228, 2011 | 316 | 2011 |
| A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy … DJ McConkey, W Choi, YU Shen, IL Lee, S Porten, SF Matin, AM Kamat, ... European urology 69 (5), 855-862, 2016 | 274 | 2016 |
| Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers X Peng, Z Chen, F Farshidfar, X Xu, PL Lorenzi, Y Wang, F Cheng, L Tan, ... Cell reports 23 (1), 255-269. e4, 2018 | 228 | 2018 |
| Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance SP Porten, JM Whitson, JE Cowan, MR Cooperberg, K Shinohara, ... Journal of Clinical Oncology 29 (20), 2795-2800, 2011 | 211 | 2011 |
| Refining patient selection for neoadjuvant chemotherapy before radical cystectomy SH Culp, RJ Dickstein, HB Grossman, SM Pretzsch, S Porten, ... The Journal of urology 191 (1), 40-47, 2014 | 199 | 2014 |
| Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma S Porten, AO Siefker‐Radtke, L Xiao, V Margulis, AM Kamat, CG Wood, ... Cancer 120 (12), 1794-1799, 2014 | 181 | 2014 |
| Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers BH Eisner, SP Porten, SK Bechis, ML Stoller The Journal of urology 183 (6), 2244-2248, 2010 | 154 | 2010 |
| The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer JM Whitson, SP Porten, JF Hilton, JE Cowan, N Perez, MR Cooperberg, ... The Journal of urology 185 (5), 1656-1660, 2011 | 130 | 2011 |
| Adaptive immune resistance to intravesical BCG in non–muscle invasive bladder cancer: Implications for prospective BCG-unresponsive trials M Kates, A Matoso, W Choi, AS Baras, MJ Daniels, K Lombardo, A Brant, ... Clinical cancer research 26 (4), 882-891, 2020 | 121 | 2020 |
| Integrated genomic analysis of the ubiquitin pathway across cancer types Z Ge, JS Leighton, Y Wang, X Peng, Z Chen, H Chen, Y Sun, F Yao, J Li, ... Cell reports 23 (1), 213-226. e3, 2018 | 95 | 2018 |
| Epidemiology, screening, and prevention of bladder cancer N Lobo, L Afferi, M Moschini, H Mostafid, S Porten, SP Psutka, S Gupta, ... European urology oncology 5 (6), 628-639, 2022 | 94 | 2022 |
| Prevalence and severity of undiagnosed urinary incontinence in women LP Wallner, S Porten, RT Meenan, MCOK Rosetti, EA Calhoun, AV Sarma, ... The American journal of medicine 122 (11), 1037-1042, 2009 | 85 | 2009 |
| Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin CE Chu, M Sjöström, EA Egusa, EA Gibb, ML Badura, J Zhu, VS Koshkin, ... Clinical Cancer Research 27 (18), 5123-5130, 2021 | 83 | 2021 |
| Discovering dominant tumor immune archetypes in a pan-cancer census AJ Combes, B Samad, J Tsui, NW Chew, P Yan, GC Reeder, D Kushnoor, ... Cell 185 (1), 184-203. e19, 2022 | 75 | 2022 |
peter carrollProfessor of Urology, university of California san franciscoVerified email at ucsf.edu
